Quantcast

Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2014-2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global
Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech &
Diagnostics 2014-2019”
report has been added to ResearchAndMarkets.com’s
offering.

The Global Collaborative R&D Partnering Terms and Agreements in Pharma,
Biotech and Diagnostics 2014-2019 report provides comprehensive
understanding and unprecedented access to the collaborative R&D deals
and agreements entered into by the worlds leading life science companies.

This report provides details of the latest collaborative R&D deals
announced in the pharmaceutical, biotechnology and diagnostic sectors.
Fully up to date with the latest information, the report provides
details of collaborative R&D deals from 2014 to 2019.

There has been a long standing willingness for parties to enter
collaborative R&D deals. Such deals enable both parties to benefit from
the upside of a big R&D win, whilst mitigating the risks of going it
alone in the risky preclinical and clinical development stages.

Collaborative R&D is a specific type of partnering deal whereby the
parties to the deal agree to collaborate on the research and development
and subsequently commercialize a compound, product or technology.

There are several forms of a collaborative R&D deal; A traditional
collaborative R&D arrangement whereby an owner of intellectual property
(the licensor) provides access to its technology to another company (the
licensee) in return for agreed payments and royalties on subsequent
sales of product(s) derived from the intellectual property.

In more recent times, licensing is often the outcome of a successful
period of collaborative R&D on the research and development of a
technology or compound, resulting in a product which can be
commercialized. In this situation, the collaborative R&D agreement
governs who has permission to commercialize and what payments are due
should commercialization proceed.

The report provides a detailed understand and analysis of how and why
companies enter collaborative R&D deals. The majority of deals are
multicomponent whereby the licensee retains either a right or option to
license to commercialize the resultant product of the research
collaboration. There are also numerous pure licensing deals whereby the
products originator takes on a development/commercialization partner in
order to maximize a technologies/products prospects.

This report contains a comprehensive listing of all collaborative R&D
deals announced since 2014 as recorded in the deals and alliances
database, including financial terms where available, plus links to
online copies of actual collaborative R&D contract documents as
submitted to the Securities Exchange Commission by companies and their
partners.

Key benefits

  • In-depth understanding of collaborative R&D deal trends since 2014
  • Analysis of the structure of collaborative R&D agreements with
    numerous real life case studies
  • Comprehensive listing of over 4,500 collaborative R&D deals since
    2014, together with deal terms, value and press release
  • Comprehensive access to actual collaborative R&D contracts entered
    into by the world’s life science companies
  • Analysis of key deal financials including headline value, upfront,
    milestone payments and royalty rates
  • Insight into the terms included in a collaborative R&D agreement,
    together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal
    terms for partner companies

Report scope

  • Trends in collaborative R&D dealmaking in the biopharma industry since
    2014
  • Analysis of collaborative R&D deal structure
  • Case studies of real-life collaborative R&D deals
  • Comprehensive listing of over 4,500 collaborative R&D deals since 2014
  • Access to collaborative R&D contract documents
  • Key financial benchmarks for headline, upfront, milestone and royalty
    rates
  • The leading collaborative R&D deals by value since 2014
  • Most active collaborative R&D dealmakers since 2014
  • The leading collaborative R&D partnering resources

Available deals and contracts are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type

Key Topics Covered:

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in collaborative R&D dealmaking

2.1. Introduction

2.2. Definition of collaborative R&D partnering

2.3. Success factors for collaborative R&D deals

2.4. When collaborative R&D can be useful

2.5. Attributes of collaborative R&D deals

2.6. Trends in collaborative R&D deals since 2014

2.6.1. Collaborative R&D dealmaking by year, 2014 to 2019

2.6.2. Collaborative R&D dealmaking by phase of development, 2014 to 2019

2.6.3. Collaborative R&D dealmaking by industry sector, 2014 to 2019

2.6.4. Collaborative R&D dealmaking by therapy area, 2014 to 2019

2.6.5. Collaborative R&D dealmaking by technology type, 2014 to 2019

2.6.6. Collaborative R&D dealmaking by most active company, 2014 to 2019

2.7. The future of collaborative R&D deals

Chapter 3 – Overview of collaborative R&D deal structure

3.1. Introduction

3.2. Pure versus multi-component collaborative R&D deals

3.3. Pure collaborative R&D agreement structure

3.3.1. Example collaborative R&D agreements

3.3.1.a. Case study 1: Marinus Pharmaceuticals – NovaMedica

3.3.1.b. Case study 2: Idenix Pharmaceuticals – Janssen Pharmaceuticals

3.4. Collaborative R&D as part of a wider alliance agreement

3.4.1. Example collaborative R&D agreements and their licensing clauses

3.4.1.a. Case study 3: 4D Molecular Therapeutics – UniQure

3.4.1.b. Case study 4: Kyowa Hakko Kirin – Ultragenyx Pharmaceuticals

3.4.2. Example licensing option right clauses in collaborative R&D deals

3.4.2.a. Case study 5: Forest Laboratories – Trevena

3.4.2.b. Case study 6: Abbvie – Receptos

Chapter 4 – Leading collaborative R&D deals

4.1. Introduction

4.2. Top collaborative R&D deals by value

Chapter 5 – Top 50 most active collaborative R&D dealmakers

5.1. Introduction

5.2. Top 50 most active collaborative R&D dealmakers

Chapter 6 – Collaborative R&D deal term financials

6.1. Introduction

6.2. Collaborative R&D partnering headline values

6.3. Collaborative R&D deal upfront payments

6.4. Collaborative R&D deal milestone payments

6.5. Collaborative R&D royalty rates

Chapter 7 – Collaborative R&D contract directory 2014 – 2019

7.1. Introduction

7.2. Collaborative R&D deals with contracts 2014 to 2019

Appendices

Appendix 1 – Collaborative R&D dealmaking by companies A-Z

Appendix 2 – Collaborative R&D dealmaking by industry sector

Appendix 3 – Collaborative R&D dealmaking by stage of development

Appendix 4 – Collaborative R&D dealmaking by therapy area

Appendix 5 – Collaborative R&D dealmaking by technology type

For more information about this report visit https://www.researchandmarkets.com/research/zq65sk/global?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Biotechnology,
Pharmaceuticals,
Diagnostics

Read the full article

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.